Enlivex Therapeutics - ADR Peer Comparison
$1.42
$-0.06
(-3.73%)
As on 28-Aug-2026 13:39EDT
Market cap
$26 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
0
P/B Ratio
0
Div. Yield
0 %
Edit
| Enlivex Therapeutics - ADR | UroGen Pharma (URGN) | Compugen - ADR | CollPlant Biotechnologies - ADR | Sol-Gel Technologies - ADR | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
26 | 2,291 | 248 | 6 | 254 |
Revenue ($ Mln) |
-- | 189 | 74 | 0 | 2 |
Net Profit ($ Mln) |
1,235.53 | -97.64 | 35.19 | -13.13 | -16.34 |
Net Margin (%) |
-- | -51.73 | 47.55 | -3,376.35 | -910.14 |
RoE (%) |
126.17 | -- | 36.76 | -185.10 | -46.08 |
Price to Earnings |
0.00 | -- | 7.07 | -- | -- |
Price-To-Book |
0.01 | 19.27 | 2.84 | 1.21 | 5.25 |
Cashflow ($ Mln)
| Enlivex Therapeutics - ADR | UroGen Pharma (URGN) | Compugen - ADR | CollPlant Biotechnologies - ADR | Sol-Gel Technologies - ADR | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-10.42 | -162.44 | 31.63 | -9.42 | 0.32 |
|
Cash Flow from Investing Activities
|
-1.32 | 61.56 | 30.00 | -0.03 | -8.58 |
|
Cash from Financing Activities
|
10.38 | 39.92 | 10.60 | 3.10 | 0.01 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Enlivex Therapeutics - ADR | UroGen Pharma (URGN) | Compugen - ADR | CollPlant Biotechnologies - ADR | Sol-Gel Technologies - ADR | |
|---|---|---|---|---|---|
|
ROCE (%)
|
126.09 | -223.36 | 43.23 | -90.21 | -22.71 |
|
ROE (%)
|
126.17 | 268.63 | 44.84 | -117.56 | -23.72 |
|
ROA (%)
|
104.94 | -63.14 | 26.00 | -77.90 | -18.63 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-- | -139.81 | 48.57 | -484.56 | -31.60 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Enlivex Therapeutics - ADR | UroGen Pharma (URGN) | Compugen - ADR | CollPlant Biotechnologies - ADR | Sol-Gel Technologies - ADR | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-- | 0.21 | 1.61 | 3.60 | 0.68 |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
8,329.17 | -20.98 | 348.35 | 30.83 | 42.09 |
|
EPS Growth (%)
|
38.38 | -0.16 | 3.35 | 0.38 | 0.42 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Enlivex Therapeutics - ADR | UroGen Pharma (URGN) | Compugen - ADR | CollPlant Biotechnologies - ADR | Sol-Gel Technologies - ADR | |
|---|---|---|---|---|---|
|
Price / Earnings
|
0.00 | -7.51 | 4.10 | -1.56 | -19.16 |
|
Price / Book Value
|
0.00 | -10.93 | 1.41 | 2.95 | 5.15 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
0.20 | -8.56 | 0.06 | -1.40 | -12.71 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Enlivex Therapeutics - ADR | UroGen Pharma (URGN) | Compugen - ADR | CollPlant Biotechnologies - ADR | Sol-Gel Technologies - ADR | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | -1.22 | 0.03 | 0.47 | 0.04 |
|
Short term debt to equity ratio
|
0.00 | -- | 0.01 | 0.13 | 0.02 |
|
Current Ratio
|
193.24 | 4.01 | 6.56 | 2.53 | 4.37 |
|
Quick Ratio
|
-- | 3.65 | -- | 2.31 | -- |
|
Interest Coverage
|
-1,153.85 | -4.08 | -- | -764.93 | -- |
Operating Efficiency Ratios
| Enlivex Therapeutics - ADR | UroGen Pharma (URGN) | Compugen - ADR | CollPlant Biotechnologies - ADR | Sol-Gel Technologies - ADR | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
-- | 30.13 | 0.40 | 0.04 | 10.15 |
|
Asset Turnover
|
0.00 | 0.45 | 0.54 | 0.16 | 0.59 |
|
Receivable days
|
-- | 88.80 | 1.41 | 44.98 | 52.40 |
|
Inventory Days
|
-- | 376.94 | -- | 105.90 | -- |
|
Payable days
|
2,540.80 | 338.46 | 82.73 | 154.71 | 3,350.92 |
|
Cash Conversion Cycle
|
-- | 127.29 | -- | -3.84 | -- |
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
